The Science Behind ViraWarn
Meet Opteev's Head of Virology
In Clinical Trials…Pre-EUA Submitted To FDA For Review


Virus Particles are
Charge Carriers!
Viruses have genetic material made of nucleic acids, which have a partial negative charge, and a protein coat of amino acids which can be neutral, negative, or positive in charge. The net charge is the cumulative charge of the genetic material and protein.


Conductive
Biosensor
ViraWarn by Opteev is able to detect this charge instantly by utilizing a proprietary Conductive Biosensor. Carbon filters in the mouthpiece of the device trap larger particles in the breath allowing the viral particles to pass through to the biosensor.


Change in
Conductivity Occurs
When virus particles come in contact with the Conductive Biosensor, a change in conductivity and a fluctuation in electrical parameters will occur.


Data Analyzed by
AI Processor
That electrical data is then analyzed by specialized Artificial Intelligence algorithms to filter out false readings, decide threshold values, and determine the result.


Signal Sent
to User
A positive or negative result is then sent to the user in the form of a RED-positive or GREEN-negative LED indicator light, while an internal HEPA filter ensures air released from the device is clean and virus-free.
Future-Proof!
Unlike Traditional COVID ‘Quick’ Tests, ViraWarn Will Continue To Accurately Detect New COVID-19 Variants.

Because ViraWarn detects viral conductivity
which is not affected by mutations.
Artificial Intelligence
ViraWarn’s Ultra-High Accuracy Is Driven By Advanced Algorithms
AI Processor filters out false readings.


Powered By Nature
Silk – A Sustainable, Biodegradable Material Is The Key To Detecting Viruses Instantly.

ViraWarn’s ultra-fast new way to self test utilizes an advanced proprietary biosensor that is made of conductive silk.
Meet Opteev's Head of Virology




The current product information is presented for information only and is not presently available for sale. The product for human breath virus detection is experimental at this point and is not yet approved by the FDA. The product is in early-stage clinical trials, and we make no claims at this point for safety or efficacy.
In Clinical Trials…Pre-EUA Submitted To FDA For Review
Yes, ViraWarn is being extensively tested internally and is in ongoing clinical trials in the US and India. These clinical trials involve participants with confirmed SARS-CoV-2 infection and are currently demonstrating an accuracy of 92%.